Home › Research › Health systems and care delivery
Penny-wise but Pound-foolish: The Hidden Costs of Step Therapy for Overactive Bladder
A. Lenore Ackerman. The Journal of Urology, 2023-03-23
Topic: Risk, prevention and care in population studies
Plain-language summary
Lenore Ackerman *Correspondence: David Geffen School of Medicine, 10833 Le Conte Ave, Box 951738, Los Angeles, CA 90095-1738 telephone: 310-794-0206; E-mail Address: [email protected] https://orcid.org/0000-0003-4192-7649 Department of Urology and Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California View All Author Informationhttps://doi.org/10.1097/JU.0000000000003430AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Overactive bladder, including symptoms of increased urinary frequency, urgency, and incontinence, is more prevalent than diabetes, affecting 1 in 6 adults in the United States.1,2 Occurring more commonly among women and older adults, untreated overactive bladder is associated with reduced quality of life, increased incidence of depression and anxiety, increased risk of experiencing falls/fractures, and increased institutionalization. The American Urological Association treatment guidelines for overactive bladder recommend pharmacological treatment with anticholinergics or β3-adrenergic receptor agonists in combination with behavioral therapy as first-line treatment or pharmacological treatment alone as second-line treatment.1 Anticholinergic medications, which have been used to treat overactive bladder for decades, may be effective for some patients but have long been recognized to result in bothersome and persistence-limiting side effects such as constipation and dry mouth. While medication substitutions require provider approval, substitutions can result in anticholinergics being dispensed to patients despite the physician's initial intent to prescribe a different treatment class because anticholinergics may have been inappropriate due to age or potential for cognitive dysfunction or falls. While generally viewed as a benign side effect, constipation alone can impart a significant burden on the health care system, with over 3.7 million office and immediate care visits each year centering on the evaluation and management of constipation (including constipation unrelated to anticholinergic use).6 In addition, constipation may impair productivity, increase psychological distress, and degrade overall quality of life. Evidence from a systematic literature review and meta-analysis supports a heightened risk of Alzheimer disease, incident
What this study adds
Evidence grade: High
This is a pooled review. This review discusses treatment guidelines for overactive bladder, a condition more common than diabetes that is linked to falls, fractures, depression and institutionalization. It does not report any findings about treating, curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ackerman, A. L. (2023). Penny-wise but Pound-foolish: The Hidden Costs of Step Therapy for Overactive Bladder. The Journal of Urology. https://doi.org/10.1097/ju.0000000000003430
Vancouver
Ackerman AL. Penny-wise but Pound-foolish: The Hidden Costs of Step Therapy for Overactive Bladder. The Journal of Urology. 2023. doi:10.1097/ju.0000000000003430. PMID: 36950931.
BibTeX
@article{ackerman2023-36950931,
author = {Ackerman, A. Lenore},
title = {{Penny-wise but Pound-foolish: The Hidden Costs of Step Therapy for Overactive Bladder}},
journal = {The Journal of Urology},
year = {2023},
doi = {10.1097/ju.0000000000003430},
pmid = {36950931},
url = {https://doi.org/10.1097/ju.0000000000003430}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Lenore Ackerman *Correspondence: David Geffen School of Medicine, 10833 Le Conte Ave, Box 951738, Los Angeles, CA 90095-1738 telephone: 310-794-0206; E-mail Address: [email protected] https://orcid.org/0000-0003-4192-7649 Department of Urology and Department of Obstetrics and Gynecology, Division of
- The American Urological Association treatment guidelines for overactive bladder recommend pharmacological treatment with anticholinergics or β3-adrenergic receptor agonists in combination with behavioral therapy as first-line treatment or pharmacological treatment alone as second-line treatment.1 Anticholinergic medications, which have been used to treat overactive bladder for decades, may be effective for some patients but have long been recognized to result in bothersome and persistence-limiting side effects such as constipation and dry mouth.
- While medication substitutions require provider approval, substitutions can result in anticholinergics being dispensed to patients despite the physician's initial intent to prescribe a different treatment class because anticholinergics may have been inappropriate due to age or potential for cognitive dysfunction or falls.
- While generally viewed as a benign side effect, constipation alone can impart a significant burden on the health care system, with over 3.7 million office and immediate care visits each year centering on the evaluation and management of constipation (including constipation unrelated to anticholinergic use).6 In addition, constipation may impair productivity, increase psychological distress, and degrade overall quality of life.
- Evidence from a systematic literature review and meta-analysis supports a heightened risk of Alzheimer disease, incident mild cognitive impairment, and cognitive impairment/decreased performance, in addition to an increased risk of dementia with anticholinergic administration.4 Step-therapy protocols may require patients to trial specific anticholinergics (eg, oxybutynin and tolterodine) that have an association with cognitive decline7 for anywhere from a month to a year before they can receive treatments (eg, β3-adrenergic receptor agonists) that have not been associated with adverse cognitive effects.
Why it matters
This review discusses treatment guidelines for overactive bladder, a condition more common than diabetes that is linked to falls, fractures, depression and institutionalization. It does not report any findings about treating, curing or preventing Alzheimer's disease.
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 53/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of Urology) |
| Journal's citation record | 3 / 4 | The Journal of Urology: journal h-index 373 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.6 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 2 / 6 | Cited 2.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author A. Lenore Ackerman: h-index 11 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Los Angeles: institution h-index 1,923 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36950931) |
| Free to read | 2 / 2 | Free to read |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/ju.0000000000003430
- PubMed: 36950931
- Original source →
- Free full text: The Journal of Urology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.